Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Two-dimensional dose finding in discrete dose space.

Kai Wang1, Anastasia Ivanova

  • 1Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7420, USA.

Biometrics
|March 2, 2005
PubMed
Summary

This study introduces a new Bayesian design for Phase I clinical trials to identify maximum-tolerated dose combinations of two agents. The proposed method is more effective than traditional one-dimensional approaches for finding optimal combination doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Competing-triggering effect models for multitype recurrent event data.

Biometrics·2026
Same author

Dynamic borrowing methods for basket trials with order restrictions.

Journal of biopharmaceutical statistics·2026
Same author

PrecISE-a biomarker-stratified adaptive trial of 5 interventions in severe asthma: Final protocol and the baseline cohort.

The Journal of allergy and clinical immunology·2026
Same author

Design characteristics of sequential multiple assignment randomised trials (SMARTs) for human health: a scoping review of studies between 2009 and 2024.

BMJ open·2025
Same author

Prediction of transition probabilities in multi-state models with nested case-control data.

Biometrics·2025
Same author

Dynamic prediction by landmarking with data from cohort subsampling designs.

Statistical methods in medical research·2025

Area of Science:

  • Clinical trial design
  • Pharmacology
  • Biostatistics

Background:

  • Phase I clinical trials aim to determine maximum-tolerated doses (MTD) for new drugs.
  • Combination therapy trials require identifying MTDs for multiple agents simultaneously.
  • Existing methods may be inefficient for finding MTD combinations.

Purpose of the Study:

  • To develop and evaluate a novel Bayesian design for Phase I trials involving two agents.
  • To identify maximum-tolerated dose combinations when doses of one agent are fixed.
  • To improve the efficiency of MTD combination identification compared to existing methods.

Main Methods:

  • A Bayesian design utilizing a parsimonious working model for dose-toxicity relationships.
  • Focus on scenarios with fixed doses of one agent and variable doses of a second agent.

Related Experiment Videos

  • Comparison of the proposed design against one-dimensional designs.

    • Main Results:

    • The proposed Bayesian design effectively identifies maximum-tolerated dose combinations.
    • The new design demonstrates superior effectiveness compared to one-dimensional designs.
    • Accurate identification of optimal combination doses is achieved.

    Conclusions:

    • The novel Bayesian design offers a more effective approach for Phase I combination trials.
    • This method enhances the identification of maximum-tolerated dose combinations.
    • The design provides a valuable tool for optimizing combination drug development.